CBD for Individuals at Risk for Alzheimer's Disease (NCT05822362) | Clinical Trial Compass
RecruitingPhase 2
CBD for Individuals at Risk for Alzheimer's Disease
United States236 participantsStarted 2024-01-19
Plain-language summary
This is a double-blind, randomized controlled trial designed to test the effects of cannabidiol (CBD) on validated biomarkers of Alzheimer's disease (AD) progression, and behavioral, neurocognitive, and clinical measures, with putative mechanisms of action.
Who can participate
Age range55 Years ā 85 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. Must be between the ages of 55 - 85 and provide valid informed consent.
ā. Participant must receive a diagnosis of Mild Cognitive Impairment after a careful cognitive and functional evaluation by a clinician.
ā. Functional Activities Questionnaire (FAQ) score of 8 or less and self-reported ability to function independently
ā. Montreal Cognitive Assessment (MoCa) score is between 18-25
ā. Participant must have a CDR score of .5 on the Clinical Dementia Rating scale (CDR), which includes an assessment of function and is often used to distinguish MCI from dementia.
ā. Must have an informant that will be utilized over the course of the 24 week study (must be the same person throughout study)
ā. Participant must pass a test of consent comprehension
ā. Must be interested in using CBD to help with cognitive function
Exclusion criteria
ā. Any other central nervous system (CNS) disease that would be expected to affect cognition, Parkinson's disease, multiple sclerosis.
ā. Any history of brain injury (e.g., concussion with significant loss of consciousness)
ā. Any significant systemic illness or unstable medical condition
ā. Current use of Parkinson's medications, antipsychotic medications, anti-seizure medications, or anticholinergic medications
ā. Current or lifetime diagnosis of a schizophrenia spectrum disorder, psychotic disorder, bipolar disorder type I \& II, cluster B personality disorders (antisocial, borderline, narcissistic, histrionic), eating disorders, as defined by the DSM-5-TR
ā. Participation in other clinical studies involving neuropsychological measures being collected more than one time per year.
ā. Reported use of other drugs (cocaine, opiates, methamphetamine, MDMA) in the past 60 days or test positive on a urine test for those drugs of abuse at baseline.
ā. Report using cannabis, including products with or without CBD, more than four times per month.